Understanding the COX-2/NSAID dilemma

Drugs

Volumn 65, Issue 14, 2005, Pages 1915-1917

  Roth, Sanford H ^a,b  

^a Arizona Research and Education   (United States)

^b Arizona Research and Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; SALICYLIC ACID; SALSALATE;

ANALGESIA; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDITORIAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HOMEOSTASIS; HUMAN; LONG TERM CARE; MORBIDITY; PEPTIC ULCER; PHARMACY; RHEUMATOLOGY; RISK ASSESSMENT; STATISTICS; STOMACH DISEASE; STROKE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; PAIN; STOMACH ULCER;

EID: 24944529930     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565140-00001     Document Type: Editorial

References (16)

1. Fries JF, Murtagh KN, Bennett M, et al. The rise and decline of nonsteroidal anti-inflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004; 50 (8): 2433-40
2. Roth SH, Bennett RE. NSAID gastropathy: recognition and response. Arch Intern Med 1987; 147: 2093-100
3. Roth SH. Nonsteroidal antiinflammatory drug gastropathy: we started it. Why don't we stop it? J Rheumatol 2005; 32 (7): 1189-ll91
4. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS Database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 2000; 7 (2): 115-21
5. Finckh A, Aronson MD. Cardiovascular risks of cyclooxygenase-2 inhibitors: where we stand now. Ann Intern Med 2005 Feb 1; 142 (3): 212-4
6. Roth SH. Salicylates revisited: are they still the hallmark of anti-inflammatory therapy? Drugs 1988; 36 (1): 1-6
7. Vane JR. Inhibition of prostaglandin synthetase as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 328-46
8. Topol EJ. Arthritis medicines and cardiovascular events: house of coxibs. JAMA 2005; 293 (3): 366-8
9. Fitzgerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Disc 2003; 2: 879-90
10. Roth SH. A new role for opioids in the treatment of arthritis. Drugs 2002; 62 (2): 255-63
11. Lin J, Zhang W, Jones A, et al. Efficacy of topical non-steroidal, anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 2004 Aug 7; 329 (7461): 324
12. Roth SH, Shainhouse JZ. A multicenter, placebo-controlled, double-blinded, clinical trial of diclofenac topical solution (Pennsaid) in the treatment of the symptoms of primary osteoarthritis of the knee. Arch Intern Med 2004; 164: 2017-23
13. Sun DC, Roth SH, Mitchell CS, et al. Upper gastrointestinal disease in rheumatoid arthritis. Am J Dig Dis 1974; 19: 405-10
14. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142 (3): 157-64
15. Food and Drug Administration. FDA issues public health advisory recommending limited use of COX-2 inhibitors. Media Release: 23 December 2004 [online]. Available from URL: http://w.w.w.fda.gov [Accessed 2005 Feb 5]
16. Roth SH. Pharmacologic approaches to musculoskeletal disorders. Clin Geriatr Med 1988; 4: 441-61